{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:29:38Z","timestamp":1791419378759,"version":"4.3.3"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009996","name":"Sigma-Tau Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.biopsych.2004.06.025","type":"journal-article","created":{"date-parts":[[2004,8,11]],"date-time":"2004-08-11T10:34:09Z","timestamp":1092220449000},"page":"418-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients"],"prefix":"10.1016","volume":"56","author":[{"given":"Linda L.","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco A.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel A.","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Regenold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Labiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2004.06.025_bib1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.1994.03950100042004","article-title":"Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine","volume":"51","author":"Altemus","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3999(02)00476-2","article-title":"The effects of vagus nerve stimulation on sleep EEG in depression. A preliminary report","volume":"54","author":"Armitage","year":"2003","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.biopsych.2004.06.025_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-977X(00)00089-4","article-title":"Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment","volume":"10","author":"Backman","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(94)00083-9","article-title":"Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures","volume":"20","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopsych.2004.06.025_bib5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1528-1157.1994.tb02482.x","article-title":"Vagus nerve stimulation for treatment of partial seizures","volume":"35","author":"Ben-Menachem","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopsych.2004.06.025_bib6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00004424-200108000-00006","article-title":"Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI","volume":"36","author":"Bohning","year":"2001","journal-title":"Invest Radiol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/clpt.1985.46","article-title":"Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid","volume":"37","author":"Bowden","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2004.06.025_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.npp.1300025","article-title":"Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans","volume":"28","author":"Carpenter","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0165-0327(02)00460-3","article-title":"Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression","volume":"79","author":"Carpenter","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2004.06.025_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0165-1781(02)00233-0","article-title":"Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania","volume":"112","author":"Carpenter","year":"2002","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2004.06.025_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/sj.npp.1300375","article-title":"Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects","volume":"29","author":"Carpenter","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00406-002-0372-7","article-title":"Converging evidence suggests that monoamine neurotransmitter turnover in human adults is associated with their season of birth","volume":"252","author":"Chotai","year":"2002","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2004.06.025_bib13","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.biopsych.2004.06.025_bib14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0006-3223(98)00382-5","article-title":"CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects","volume":"45","author":"Cremniter","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib15","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0006-3223(93)90103-K","article-title":"Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers","volume":"33","author":"De Bellis","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1176\/ajp.150.4.656","article-title":"Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression","volume":"150","author":"De Bellis","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0924-977X(99)00016-4","article-title":"Reduced cerebrospinal HVA concentrations and HVA\/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls","volume":"9","author":"Engstrom","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145703003250","article-title":"Vagus nerve stimulation (VNS): Utility in neuropsychiatric disorders","volume":"6","author":"George","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib18","unstructured":"Goodwin FK, Jamison KR (1990): Biochemical and pharmacological studies. Manic-Depressive Illness. New York: Oxford University Press, 416\u2013502."},{"key":"10.1016\/j.biopsych.2004.06.025_bib19","series-title":"ECDEU Assessment Manual","author":"Guy","year":"1976"},{"key":"10.1016\/j.biopsych.2004.06.025_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/WNL.51.1.48","article-title":"Vagus nerve stimulation therapy for partial-onset seizures","volume":"51","author":"Handforth","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1528-1157.1998.tb01448.x","article-title":"Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy","volume":"39","author":"Henry","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopsych.2004.06.025_bib23","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/archpsyc.1987.01800240054008","article-title":"Monoamine neurotransmitter interactions and the prediction of antidepressant response","volume":"44","author":"Hsiao","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0893-133X(01)00344-X","article-title":"Central nervous system monoamine correlates of social dominance in cynomolgus monkeys (Macaca fascicularis)","volume":"26","author":"Kaplan","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1528-1157.1998.tb01155.x","article-title":"Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation","volume":"39","author":"Krahl","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopsych.2004.06.025_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.npp.1380241","article-title":"Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls","volume":"12","author":"Leckman","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0006-3223(98)00078-X","article-title":"Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression","volume":"45","author":"Little","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0022-3956(02)00013-4","article-title":"Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency\/dose dependent effects","volume":"36","author":"Lomarev","year":"2002","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2004.06.025_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0006-3223(01)01343-9","article-title":"Vagus nerve stimulation (VNS) for major depressive episodes","volume":"51","author":"Marangell","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0447.1989.tb10307.x","article-title":"Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid","volume":"79","author":"Martensson","year":"1989","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2004.06.025_bib31","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1212\/WNL.53.8.1731","article-title":"Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05","volume":"53","author":"Morris","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0920-1211(95)00035-9","article-title":"Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve","volume":"22","author":"Naritoku","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopsych.2004.06.025_bib33","series-title":"Handbook of Psychopharmacology, Volume 13: Biology of Mood and Antianxiety Drugs","first-page":"147","article-title":"Approaches to brain amines in psychiatric patients: A reevaluation of cerebrospinal fluid studies","author":"Post","year":"1978"},{"key":"10.1016\/j.biopsych.2004.06.025_bib34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archpsyc.1985.01790350045009","article-title":"Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites","volume":"42","author":"Potter","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/clpt.1987.195","article-title":"The effects of antidepressants on the cerebrospinal fluid homovanillic acid\/5-hydroxyindoleacetic acid ratio","volume":"42","author":"Risby","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2004.06.025_bib36","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1176\/appi.ajp.159.6.1053","article-title":"Higher levels of CSF homovanillic acid in recently abstinent cocaine-dependent patients","volume":"159","author":"Roy","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"suppl 1 pt A","key":"10.1016\/j.biopsych.2004.06.025_bib37","doi-asserted-by":"crossref","first-page":"677A","DOI":"10.1097\/00002826-199201001-00350","article-title":"Monoaminergic actions of ECT","volume":"15","author":"Rudorfer","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib38","first-page":"133","article-title":"Disparate biochemical actions of electroconvulsive therapy and antidepressant drugs","volume":"4","author":"Rudorfer","year":"1988","journal-title":"Convuls Ther"},{"key":"10.1016\/j.biopsych.2004.06.025_bib39","first-page":"396","article-title":"ECT alters human monoamines in a different manner from that of antidepressant drugs","volume":"24","author":"Rudorfer","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.biopsych.2004.06.025_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0006-3223(99)00304-2","article-title":"Vagus nerve stimulation (VNS) for treatment-resistant depressions","volume":"47","author":"Rush","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib42","first-page":"53","article-title":"The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression","volume":"14","author":"Sackeim","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0893-133X(01)00271-8","article-title":"Vagus nerve stimulation (VNS) for treatment-resistant depression","volume":"25","author":"Sackeim","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib44","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneur.1996.00550110128021","article-title":"Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group","volume":"53","author":"Salinsky","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib45","first-page":"S15","article-title":"Vagus nerve stimulation therapy summary","volume":"59","author":"Schachter","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2004.06.025_bib46","first-page":"1","article-title":"Monoamine metabolites in human cerebrospinal fluid","volume":"63","author":"Scheinin","year":"1985","journal-title":"Med Biol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199702000-00003","article-title":"Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors","volume":"17","author":"Sheline","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib48","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/sj.npp.1300231","article-title":"Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism","volume":"28","author":"Sher","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 3II","key":"10.1016\/j.biopsych.2004.06.025_bib49","doi-asserted-by":"crossref","first-page":"I48","DOI":"10.1007\/PL00007826","article-title":"Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease","volume":"248","author":"Shimamoto","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp.74.7.918","article-title":"New evidence for an association between the CSF HVA","volume":"74","author":"Soderstrom","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2004.06.025_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0378-4347(99)00283-2","article-title":"Combined method for the determination of gamma-aminobutyric acid and beta-alanine in cerebrospinal fluid by stable isotope dilution mass spectrometry","volume":"732","author":"Struys","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.biopsych.2004.06.025_bib52","series-title":"Nucleus of the Solitary Tract","article-title":"Ascending projections of the solitary tract nucleus","author":"Ter Horst","year":"1994"},{"key":"10.1016\/j.biopsych.2004.06.025_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00004691-200109000-00002","article-title":"The mechanism of action of vagus nerve stimulation for refractory epilepsy","volume":"18","author":"Vonck","year":"2001","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.biopsych.2004.06.025_bib54","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1528-1157.1999.tb00818.x","article-title":"Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius","volume":"40","author":"Walker","year":"1999","journal-title":"Epilepsia"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322304007036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322304007036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:56:17Z","timestamp":1762098977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322304007036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0006322304007036"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2004.06.025","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2004.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}